Tenderwize
Zurück zur Suche

Medicinal product with olodaterol and tiotropium bromide (ATC: R03AL06)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Apr 29, 2027 · 247 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Olodaterol und Tiotropiumbromid (ATC: R03AL06)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated contract value or budget is disclosed, so potential revenue cannot be assessed.

If the authority awards exclusive contracts during the term, the open-house contracts will be terminated.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for finished medicinal products containing olodaterol and tiotropium bromide (ATC: R03AL06)
  • Open-house model: any qualified pharmaceutical company can join at any time
Vollständige Zusammenfassung anzeigen

This is an open-house model for non-exclusive discount agreements under § 130a Abs. 8 SGB V for finished medicinal products containing the active substances olodaterol and tiotropium bromide (ATC: R03AL06). The contracting authority is AOK Sachsen-Anhalt. Any qualified pharmaceutical company can join at any time under standard terms. The contract runs from 1 July 2025 to 30 June 2027 (max 24 months). There is no estimated value provided. The procedure is not a public procurement under EU law despite using an open procedure notice form. Submission is via postal mail or electronically with qualified electronic signature. The deadline for submission is 30 April 2027, but the model allows participation at any time until that date.

Risiken

No estimated contract value or budget is disclosed, so potential revenue cannot be assessed.

If the authority awards exclusive contracts during the term, the open-house contracts will be terminated.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or a group of pharmaceutical companies

Administrative

  • Complete and sign the participation documents
  • Submit participation documents via postal mail or electronically with qualified electronic signature

Zuschlagskriterien

Lot 1

No award criteria defined; open to all qualifying companies.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Medicinal product with olodaterol and tiotropium bromide (ATC: R03AL06)

Non-exclusive discount agreements for finished medicinal products containing olodaterol and tiotropium bromide (ATC: R03AL06) under an open-house model. Any eligible pharmaceutical company can conclude a contract at any time. Contract duration maximum 24 months ending 30 June 2027. The contract may be terminated if the authority awards exclusive contracts later.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria defined; open to all qualifying companies.

Frist

Deadline Apr 29, 2027

Vergabedetails

Veröffentlichungsdatum
18 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
320165-2025

Dokumente (1)

Ähnliche Ausschreibungen